RNA metabolism-focused Gotham Therapeutics launches with $54M Series A round
The company, focused on epitranscriptomics, launched with backing from Versant Ventures, Forbion, GSK's venture capital arm, Celgene and others.
Accent Therapeutics launches with $40 million Series A round
Company will pursue RNA-modifying protein targets to discover and develop new treatments in oncology.
presented by
Improving Medical Billing to Cut Payment Bottlenecks
Yusuf Qasim, President of Payments Optimization at Zelis, discussed how the company is transforming healthcare payments from a fragmented, patchwork system into a modern, digital infrastructure.